Here is the design of a clinical trial:

Official Title: Faecal Microbiota Transplantation to Prevent Complications, Progression and Mortality of Liver Cirrhosis

Included conditions:
- Liver Cirrhosis

Study Armgroups:
- {'label': 'Faecal microbiota transplantation', 'type': 'EXPERIMENTAL', 'description': 'The patients will receive three applications of FMT consisting of 50 g cryopreserved, homogenized faeces from healthy donors. The faecal material will be dispensed into double-coated, acid-resistant enterocapsules or cryobags. Faeces will be screened according to international guidelines.', 'interventionNames': ['Biological: Faecal microbiota transplantation']}
- {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'The placebo products is produced from a suspension of glycerol, saline and food colouring and cannot be distinguished from the active FMT products.', 'interventionNames': ['Biological: Placebo']}

Interventions:
- {'type': 'BIOLOGICAL', 'name': 'Faecal microbiota transplantation', 'description': 'All participant will receive three applications of either FMT or placebo and afterwards followed for 1 year.', 'armGroupLabels': ['Faecal microbiota transplantation'], 'otherNames': ['FMT']}
- {'type': 'BIOLOGICAL', 'name': 'Placebo', 'description': 'Placebo', 'armGroupLabels': ['Placebo']}

Primary Outcomes:
- {'measure': 'Time to death or new episode of acute decompensation requiring intervention in FMT versus placebo-treated patients.', 'description': 'Using data from the patient journals, we will be able to examine the exact time to event in each of the patients. To compare the two groups, hazard ratios will be calculated.', 'timeFrame': '1 year'}

Please estimate the sample size based on the assumption: 
Statistical significance level of 0.05, power of 80%, 1-year risk of new decompensation or death is 60%
Sample size estimation
          We will use a statistical significance level of 0.05 and aim for a power of 80%. In patients with decompensated liver cirrhosis, the 1-year risk of new decompensation or death is predicted to be 60%.33 47 Previous studies found a strong effect of rifaximin on the recurrence of HE (HR 0.42),48 and an effect of beta-blockers on decompensation (HR 0.51)49 in patients with compensated liver cirrhosis. To be able to detect an effect of FMT with an HR of at least 0.60 (a conservative presumption of a weaker treatment response than reported in the other studies), we need to randomise 220 patients with 110 in each arm.